

APASL Oncology 2024 Chiba

*“Genomics Meets Immunology:
Interdisciplinary Approach for Liver Cancer”*

Scientific Program



APASL Oncology 2024 Chiba Scientific Program

Day 1: September 24 (Tuesday) 2024

Room 1 (The Club Fuji AB)

8:30-8:40 Opening Ceremony

Opening Remarks: Dr. Naoya Kato, President of APASL Oncology 2024 Chiba

8:40-10:20 Session 1: Current Insights into Molecular Pathways and Mechanisms in Liver Cancer Development

Moderators: Dr. Lai Wei (China), Dr. Motoyuki Otsuka (Japan), Dr. Taro Yamashita (Japan)

Commentators: Dr. Yujin Hoshida (USA), Dr. Takahiro Kodama (Japan)

S1-1 Deciphering Liver Cancer: Molecular Pathways, Mechanisms, and Identifying High-Risk Groups for Carcinogenesis and Recurrence

Dr. Yujin Hoshida (USA)

S1-2 Leveraging Genomic Insights to Advance Liver Cancer Diagnosis and Treatment

Dr. Tatsuhiko Shibata (Japan)

S1-3 Liver Metabolism as a Driver of Hepatocarcinogenesis: Emerging Concepts and Future Directions

Dr. Hayato Nakagawa (Japan)

S1-4 Unraveling the Complexity of Tumor Heterogeneity in Hepatocellular Carcinoma: Intra-tumoral and Inter-tumoral Perspectives

Dr. Yosuke Hirotsu (Japan)

S1-5 Carcinogenesis and Its Evolution of Primary Liver Cancers from a Pathological Perspective

Dr. Mina Komuta (Japan)

10:30-11:10 Special Lecture 1: Hepatitis Treatment: A Long-Term Investment in Liver Cancer Prevention and Survival

Moderators: Dr. Diana A. Payawal (Philippines), Dr. Norifumi Kawada (Japan)

SL1-1 Prevention of Primary Liver Cancer, China Perspective

Dr. Lai Wei (China)

**SL1-2 Management of Portal Hypertension and its Complications in HCC:
A 2024 Update**

Dr. Shiv K Sarin (India)

11:20-12:20 Session 2: APASL HCC Guideline and the Endeavor of A-HOC

Moderators: Dr. Shiv K Sarin (India), Dr. Masao Omata (Japan)

Commentators: Dr. Oidov Baatarkhuu (Mongolia), Dr. Lai Wei (China)

S2-1 Landscape of Western HCC Guidelines

Dr. Arndt Vogel (Canada)

**S2-2 The Latest APASL Clinical Practice Guideline on Systemic Therapy for
Hepatocellular Carcinoma**

Dr. George Lau (China)

S2-3 A-HOC Start-up and Current State

Dr. Hitoshi Mochizuki (Japan)

12:30-13:30 Luncheon Seminar 1 (Gilead Sciences K.K.)

Moderator: Dr. Naoki Morimoto (Japan)

“Current Topics on Viral Hepatitis”

**LS1-1 Hepatitis C Treatment Progress Towards Elimination and Post-SVR
Issues**

Dr. Toshifumi Tada (Japan)

**LS1-2 Innovative Strategies for Treating HBV-Related HCC: Insights from
Basic Research**

Dr. Motoyuki Otsuka (Japan)

13:40-15:20 Session 3: Advances in Systemic Treatment Options for Liver Cancer

Moderators: Dr. Rino Gani (Indonesia), Dr. Masafumi Ikeda (Japan), Dr. Masayuki Kurosaki (Japan),

Commentators: Dr. George Lau (China), Dr. Arndt Vogel (Canada)

**S3-1 Current Systemic Therapy in Liver Cancer: Present Achievements and
Future Directions**

Dr. Arndt Vogel (Canada)

**S3-2 Advancing Systemic Therapy for Liver Cancer: Clinical Practice Insights
and Research Initiatives to Meet Unmet Needs**

Dr. Changhoon Yoo (Korea)

S3-3 Harnessing the Power of Real-World Data to Address Clinical Challenges in Systemic Therapy for Advanced Hepatocellular Carcinoma

Dr. Sadahisa Ogasawara (Japan)

S3-4 Pushing the Boundaries of Liver Cancer Treatment: Synergizing Locoregional Therapy and Immunotherapy

Dr. Masatoshi Kudo (Japan)

S3-5 Personalized Approaches to Liver Cancer Management: Molecular and Immunological Landscape to Develop Novel Strategies

Dr. Shinji Tanaka (Japan)

15:30-16:30 Sponsored Seminar 1 (Eisai Co., Ltd.)

Moderator: Dr. Ryosuke Tateishi (Japan)

SS1 Pushing the Envelope for Surgical Management of Advanced Hepatocellular Carcinoma

Dr. Junichi Shindoh (Japan)

16:40-17:40 Plenary Session

Moderators: Dr. Jose Sollano (Philippines), Dr. Tatsuya Yamashita (Japan)

Commentators: Dr. Hayato Hikita (Japan), Dr. Kaoru Tsuchiya (Japan)

O-1 10041

Long-term Hepatocellular Carcinoma Occurrence Rate after Administration of Nucleos(t)ide Analogues in Patients with Persistent HBV Infection

Dr. Kazuhiro Murai (Japan)

O-2 10016

Spatial Omics Analysis of the Proximity of PD-L1(+) Tumor-Associated Macrophage and CD8T cell Interaction Promoting Hepatocellular Carcinoma Progression

Dr. Takuto Nosaka (Japan)

O-3 10064

Comparative Pathological and Comprehensive Genomic Analysis for Differential Diagnosis between IM and MC

Dr. Kenji Amemiya (Japan)

O-4 10118

Relationship between Anti-tumor Response and Immune-mediated Adverse Events Requiring High-dose Corticosteroids in Unresectable Hepatocellular Carcinoma Treated with Durvalumab plus Tremelimumab

Dr. Takanori Ito (Japan)

O-5 10154

Prognostic Factors after Carbon-ion Rradiotherapy: A Study Based on Multi-institutional Registry Data

Dr. Kei Shibuya (Japan)

O-6 10163

Contour Prognostic Model: Effect of Diameter and Number of Hepatocellular Carcinomas on Survival after Resection, Trans-Arterial Chemoembolization, and Ablation (The Liver Cancer Study Group of Japan)

Dr. Yoshikuni Kawaguchi (Japan)

17:50-18:50 Poster Session Day 1

At Room 2 “The Club Fuji C” , 1st Floor, Sheraton Grande Tokyo Bay Hotel

19:00-19:20 Awarding Ceremony of Day 1

At Room “Kegon”, 1st Floor, Sheraton Grande Tokyo Bay Hotel

19:20-20:30 Welcome Reception

At Room “Kegon”, 1st Floor, Sheraton Grande Tokyo Bay Hotel

Day 1: September 24 (Tuesday) 2024

Room 2 (The Club Fuji C)

12:30-13:30 Luncheon Seminar 2 (Chugai Pharmaceutical Co., Ltd.)

Moderator: Dr. Masayuki Kurosaki (Japan)

LS2-1 Remaining Clinical Questions and Unmet Needs in the Era of Immunotherapy for Unresectable Hepatocellular Carcinoma

Dr. Takeshi Terashima (Japan)

LS2-2 Future Perspectives of Systemic Chemotherapy and Surgery in the Treatment of Hepatocellular Carcinoma

Dr. Shohei Komatsu (Japan)

15:30-16:30 Sponsored Seminar 2 (AbbVie GK)

Moderator: Dr. Tadashi Ikegami (Japan)

SS2 DAA Treatment for Chronic Hepatitis C and Future Challenges

Dr. Nobuharu Tamaki (Japan)

Day 2: September 25 (Wednesday) 2024

Room 1 (The Club Fuji AB)

7:30-8:30 Morning Seminar 1 (Incyte Biosciences Japan G.K.)

Moderator: Dr. Masayuki Otsuka (Japan)

MS1 New Treatment Strategy for Intrahepatic Cholangiocarcinoma

Dr. Makoto Ueno (Japan)

8:40-9:40 Session 4: From Mechanisms to Treatment: Targeting the Tumor

Microenvironment and Immune Landscape

Moderators: Dr. Tatsuya Kanto (Japan), Dr. Yasuhito Tanaka (Japan)

Commentators: Dr. Carmen Wong (China)

S4-1 Tumor Microenvironment and Immune Response in Cancer

Dr. Yosuke Togashi (Japan)

S4-2 Advancements and Future Directions in the Study of the Immune Landscape of Liver Cancer

Dr. Carmen Wong (China)

S4-3 Challenging in Biomarker Discovery: Targeting the Tumor Microenvironment in Hepatocellular Carcinoma

Dr. Takahiro Kodama (Japan)

9:50-10:50 Sponsored Seminar 3 (Chugai Pharmaceutical Co., Ltd.)

Moderator: Dr. Masafumi Ikeda (Japan)

SS3 Real-World Clinical Impact of Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma - A 4-Year Experience

Dr. Teiji Kuzuya (Japan)

11:00-11:40 Special Lecture 2: Hepatology in Asia: Navigating the Landscape of Liver Diseases

Moderators: Dr. Kadir Dokmeci (Turkey), Dr. Osamu Yokosuka (Japan)

SL2-1 HCC Etiology, Incidence, Diagnosis, Management and Survival in Mongolia, Update of A-HOC Studies

Dr. Jazag Amarsanaa (Mongolia)

SL2-2 Hepatology in Asia: Navigating the Landscape of Liver Diseases (HCC)

Dr. Masao Omata (Japan)

11:50-12:50 Luncheon Seminar 3 (AbbVie GK)

Moderator: Dr. Yoshiyuki Ueno (Japan)

“Topics on Treatment of Liver Diseases, HCV Infection and HCC”

LS3-1 Multidisciplinary Treatment Including Ultra-FP, iCIs and Ablation Therapy should be Considered to Control HCC

Dr. Yasuteru Kondo (Japan)

LS3-2 Pharmacokinetics of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection

Dr. Hironao Okubo (Japan)

13:00-15:00 Session 5: Integrated Therapeutic Strategies for Liver Cancer: A Multidisciplinary Perspective

*Moderators: Dr. Tawesak Tanwandee (Thailand), Dr. Kiyoshi Hasegawa (Japan),
Dr. Shuntaro Obi (Japan), Dr. Naoya Sakamoto (Japan)*

Commentators: Dr. Stephen Lam Chan (China), Dr. Yi-Hsiang Huang (Taiwan)

S5-1 From Early to Advanced Stages: Navigating Hepatocellular Carcinoma Treatment with Systemic Therapy

Dr. Stephen Lam Chan (China)

S5-2 Multifaceted Strategies for Hepatocellular Carcinoma in Asia: Improving Patient Outcomes with Optimal Treatment Modalities

Dr. Yi-Hsiang Huang (Taiwan)

S5-3 Surgical Resections in Hepatocellular Carcinoma: Evolving in Tandem with Advancements in Systemic Therapy

Dr. Shinji Itoh (Japan)

S5-4 The Role of Percutaneous Ablation in the Treatment of Liver Cancer: A Response to Shifting Disease Patterns and Treatment Landscapes

Dr. Ryosuke Tateishi (Japan)

S5-5 The Evolving Landscape of Transarterial Therapy for Liver Cancer: Current Practices and Emerging Trends

Dr. Toshihiro Tanaka (Japan)

S5-6 Radiation Therapy in Liver Cancer: Insights into Current Impact and Future Prospects

Dr. Masaru Wakatsuki (Japan)

15:10-16:10 Sponsored Seminar 5 (FUJIFILM Wako Pure Chemical Corporation)

Moderator: Dr. Masao Omata (Japan)

SS5 **AFP-L3: An Old and New Marker Specific for the Management of HCC**

Dr. Hidenori Toyoda (Japan)

16:20-17:20 Poster Session Day 2

At Room 2 “The Club Fuji C” , 1st Floor, Sheraton Grande Tokyo Bay Hotel

17:30-17:50 Awarding Ceremony of Day 2

17:50-17:55 Closing Ceremony

Closing Remarks: Dr. Naoya Kato, President of APASL Oncology 2024 Chiba

Day 2: September 25 (Wednesday) 2024

Room 2 (The Club Fuji C)

7:30-8:30 Morning Seminar 2 (Miyarisan Pharmaceutical Co., Ltd.)

Moderator: Dr. Hitoshi Yoshiji (Japan)

MS2 **Gut Microbiota in Host Health and Diseases Including Gastrointestinal Cancers**

Dr. Hiroshi Ohno (Japan)

9:50-10:50 Sponsored Seminar 4 (Gilead K.K.)

Moderator: Dr. Kazumoto Murata (Japan)

SS4 **Prediction and Prevention of Hepatocellular Carcinoma in Chronic Liver Diseases**

Dr. Taro Yamashita (Japan)

11:50-12:50 Luncheon Seminar 4 (Eisai Co., Ltd.)

Moderator: Dr. Masatoshi Kudo (Japan)

“Treatment Strategy for Hepatocellular Carcinoma Focused on Tumor Microenvironment”

LS4-1 Hepatocellular Carcinoma Treatment in the Era of Combined Immunotherapy -Future Role of Lenvatinib in Light of the Tumor Immune Microenvironment-

Dr. Naoto Fujiwara (Japan)

LS4-2 Lenvatinib-based Treatment Strategy for Unresectable Hepatocellular Carcinoma

Dr. Issei Saeki (Japan)

16:20-17:20 Poster Session Day 2
